-
- 2023.06.28
-
Notice of Board of Directors Appointments
-
What's new
- Notice of Board of Directors Appointments 2023/06/28
- Haruki Kusaka, Director of Clinical Development Dept. receives Outstanding Leadership Award at HEALTH 2.0 Conference (Dubai, UAE) 2023/06/26
- LAT1 inhibitor Nanvuranlat (development code: JPH203): Significant improvement in biliary tract cancer with high LAT1 expression, extrahepatic cholangiocarcinoma, and gallbladder cancer 2023/06/05
- J-Pharma announces Publication of the Abstract on the Japan Phase 2 study of nanvuranlat (development code: JPH203) for advanced refractory biliary tract cancer patients at the American Society of Clinical Oncology (ASCO) Annual Meeting. Nanvuranlat is an L-type amino acid transporter 1 (LAT1) inhibitor 2023/05/26
- At the 2023 ASCO Annual meeting, the latest information on the Japan Phase II study of Nanvuranlat (development code: JPH203) will be announced. Nanvuranlat is a novel L-type amino acid transporter 1 (LAT1) inhibitor for refractory biliary tract cancer patients. 2023/04/27
-
Monthly
- 2023.06 (3)
- 2023.05 (1)
- 2023.04 (1)
- 2023.03 (2)
- 2023.01 (3)
- 2022.12 (2)
- 2022.05 (1)
- 2022.04 (1)
- 2022.01 (1)
- 2021.11 (1)
- 2021.07 (1)
- 2021.03 (2)
- 2021.02 (1)
- 2021.01 (2)
- 2020.07 (1)
- 2020.06 (1)
- 2019.12 (1)
- 2019.04 (1)
- 2018.12 (1)
- 2018.07 (1)
- 2018.05 (1)
- 2018.03 (1)
- 2018.01 (1)
- 2017.09 (1)
- 2016.05 (1)
- 2015.11 (1)
- 2015.04 (1)
- 2015.02 (1)